Gameto lands $33 million to advance women’s reproductive health

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Female reproductive longevity biotech is targeting fertility, ovarian disease, menopause and beyond.

Women’s health biotech Gameto has successfully closed a $33 million Series B financing round to advance its reproductive health programs. While the new funding will primarily support the clinical development of Fertilo, the company’s investigational fertility solution that matures eggs outside the body, Gameto’s longer-term goals are more longevity-focused.

Fertility rates in the US have reached their lowest in a century and, as people live longer, many women can now expect to spend more of their lives in menopause than fertile due to the premature aging of the female reproductive system. Gameto is on a mission to solve menopause, and aims to synchronize the pace of ovarian aging to the rate of aging in other organs.

“The pathways that drive ovarian aging are similar to those that drive systemic aging, but they just occur faster in the ovary,” Dr Dina Radenkovic, CEO of Gameto told us previously.

Gameto co-founder Dina Radenkovic at work in the lab.

The oversubscribed funding round, which brings Gameto’s total funding to $73 million, was led by Two Sigma Ventures and RA Capital, with participation from existing investors, including Insight Partners, Future Ventures, and BOLD Capital Partners. Individual investors, including Olivia Walton, Stacey Bendet Eisner, and Chelsea Hirschhorn, also participated. The company secured a $20 million Series A round in 2022.

“These funds will support our late-stage clinical development in the US, post-market surveillance outside the US and the creation of a commercial operations function,” said Radenkovic. “I believe that each small step we take in investing in women’s health can lead to a giant leap in medical breakthroughs and innovation.”

Highlighting the reproductive challenges facing women today, RA Capital Management’s Peter Kolchinsky said, “To contemplate the importance of easing that burden, of expanding the freedom of many to have children when they are ready, it’s hard to overestimate the potential impact of such an advance on humanity, for all of our society, for the rest of time.”

READ MORE: Our exclusive interview with Gameto founder Dina Radenkovic

Martin Varsavsky, Chairman of Gameto, is speaking on female reproductive longevity at Founders Longevity Forum – FIND OUT MORE.

Photographs courtesy of Gameto
LTUI: 2174

Gameto

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Gameto is a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health using proprietary cell engineering technology. The company creates engineered ovarian support cells derived from induced pluripotent stem cells to enable egg maturation outside the body, substantially reducing the duration and hormonal burden of traditional in vitro fertilization protocols. Gameto's platform addresses multiple conditions affecting women's reproductive health, including infertility, menopause, and ovarian disease. The company's lead program, Fertilo, is currently in Phase 3 clinical trials in the United States and has facilitated multiple healthy births in countries where it has received regulatory approval.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE